Kurahara et al. demonstrated that low expression of GLUT-1 in the primary PDAC tumor is associated with a better prognosis, increasing therapeutic response to neoadjuvant treatment in comparison to those patients with high GLUT-1 expression (Kurahara et al., 2018). Here, SLC2A1 is linked to neoplasm.